This suggests that the poor response to immunotherapy in NSCLC patients may be associated with upregulation of genes such as LPL and the ANX family, leading to dysregulation of lipid metabolism and consequently reduced HDL levels. This evidence concerns the gene LPL and non-small cell lung carcinoma.